Vor Biopharma Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
VOR Nasdaq 2830 www.vorbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Vor Biopharma Inc.

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value - May 8th, 2025 6:30 am
Here's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash Wisely - Mar 31st, 2025 6:52 am
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update - Mar 20th, 2025 2:05 pm
Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials - Feb 13th, 2025 6:00 am
Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference - Feb 3rd, 2025 6:00 am
Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross - Jan 27th, 2025 7:55 am
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors - Jan 8th, 2025 7:00 am
Vor Biopharma Secures $55.6M for Cancer Therapy Trials - Dec 28th, 2024 7:27 am
Vor Bio Secures $55.6 Million in PIPE Financing, Shares Surge Nearly 47% - Dec 27th, 2024 12:43 pm
Vor Bio Announces $55.6 Million Private Placement - Dec 27th, 2024 7:00 am
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design - Dec 9th, 2024 5:30 am
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update - Nov 7th, 2024 2:05 pm
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer - Sep 30th, 2024 5:00 am
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies - Sep 5th, 2024 2:01 pm
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update - Aug 8th, 2024 2:05 pm
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Aug 2nd, 2024 2:01 pm